Sarcopenia
Drug research and approvals for sarcopenia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 207 studies of sarcopenia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 207
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Safety and Feasibility of an Integrated Fabric-Type Orthosis for Gait and Balance Improvement in Geriatric PatientsNCT07945288 · Not applicable · Seoul National University Hospital · starts Jun 17, 2026
- Exercise and Nutritional Intervention in Older Adults With Sarcopenia (Spleen-Kidney Deficiency Pattern)NCT07937930 · Not applicable · Shanghai Yueyang Integrated Medicine Hospital · starts Oct 17, 2026
- Multimodal Assessment of Sarcopenia Using Shear Wave Elastography, Dual-Energy X-ray Absorptiometry, Bioelectrical…NCT07915310 · Not reported · Kaohsiung Veterans General Hospital. · starts Oct 21, 2026
- Sarcopenia and Training Outcomes in Post-cardiac Surgery PatientsNCT07908472 · Not reported · Universitaire Ziekenhuizen KU Leuven · starts Feb 5, 2026
- Strength and Dual-Task on Sarcopenia in People With Parkinson's DiseaseNCT07907302 · Not applicable · University of Valencia · starts Jan 11, 2027
- Resistance vs Aerobic Prehabilitation Before Colorectal Cancer SurgeryNCT07896174 · Not applicable · Semmelweis University · starts May 27, 2026
- Low Load Blood Flow Restriction Resistance Training in Colorectal Cancer Related SarcopeniaNCT07874035 · Not applicable · Ahmed Adel Ahmed Elsayed Ali Radwan · starts May 17, 2026
- Clinical Trial of CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of SarcopeniaNCT07865676 · Phase 1 / Phase 2 · GuangZhou Cellgenes Biotechnology Co., Ltd. · starts Apr 30, 2026
- GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without DiabetesNCT07858864 · Not reported · Istanbul Saglik Bilimleri University · starts May 30, 2026
Phase 3 1
Phase 2 12
- BimagrumabActivin receptor type-2B antagonist
- Omega-3-ACID ethyl esters
- LosartanType-1 angiotensin II receptor antagonist
- TestosteroneAndrogen Receptor agonist
- SomatropinGrowth hormone receptor agonist
- Nandrolone decanoateAndrogen Receptor agonist
- MK-0773Androgen Receptor modulator
- TrevogrumabGrowth/differentiation factor 8 inhibitor
- Maltodextrin
- Olive oil
- Creatine
- 20-hydroxyecdysone
Phase 1 or earlier 9
- NitroprussideSoluble guanylate cyclase activator
- SirolimusFK506-binding protein 1A inhibitor
- Insulin humanInsulin receptor agonist
- ErgocalciferolVitamin D receptor agonist
- TilarginineNitric oxide synthase inhibitor
- Amino acids
- Leucine
- Cetylpyridinium
- UbidecarenoneSupplement
How its trials ended
887 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 110 whose ending is known, 55% met their primary endpoint, 13% missed it and 32% stopped early.
- Completed, result not reported35540%
- Ongoing26430%
- Status unknown15818%
- Met its primary endpoint617%
- Stopped: other or unclear253%
- Missed its primary endpoint142%
- Stopped: enrollment or feasibility71%
- Stopped: safety1<1%
- Stopped: sponsor or business decision1<1%
- Stopped: funding1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA